{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:02Z","timestamp":1790727002676,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant struma ovarii (MSO) is a unique type of ovarian malignancy that data on the survival outcome is limited and management strategy remains controversial due to its extreme rarity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To investigate the clinical characteristics and treatment options in patients with MSO confined to the ovary, while also evaluating the recurrent-free survival (RFS) and overall survival (OS) rate in this population, a retrospective study was conducted. One hundred twenty-five cases of MSO confined to the ovary were enrolled and their clinical characteristics, treatment strategies, and results of follow-up were analyzed. OS and RFS were assessed by Kaplan-Meier analyses and Cox regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most common pathological subtype in this cohort was papillary carcinoma (44.8%). Other reported subtypes, in order of prevalence, were follicular variant of papillary carcinoma, follicular carcinoma, and mixed follicular-papillary carcinoma. Surgical treatment options varied in this cohort that 8.0% of the patients received ovarian cystectomy, 33.6% underwent unilateral salpingo-oophorectomy (USO), 5.6% received bilateral salpingo-oophorectomy (BSO), 21.6% received total abdominal hysterectomy with BSO (TAH\/BSO), and 17.6% were treated with debulking surgery; 20.0% of them received radioiodine therapy (RAI). Twenty-seven patients experienced recurrence with a median RFS of 14.0\u2009years (95% confidence interval [CI], 9.5\u201318.5). The 5-year and 10-year recurrent rate were 27.1, 35.2%, respectively. Eight patients died during follow-up, with five attributed to MSO; the 5-year, 10-year, and 20-year OS rate was 95.3, 88.7 and 88.7%, respectively. However, the univariate and multivariate Cox regression showed no potential risk factor for RFS and OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with MSO confined to the ovary had an excellent survival outcome, despite varied treatment strategies, and the recurrent rate was relatively high. We recommend USO as the preferred surgical option in this population since more aggressive surgery does not improve outcomes and the benefits of RAI are uncertain.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08118-7","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T10:03:40Z","timestamp":1617962620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary"],"prefix":"10.1186","volume":"21","author":[{"given":"Sijian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"4","key":"8118_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00004347-199310000-00008","volume":"12","author":"K Devaney","year":"1993","unstructured":"Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol. 1993;12(4):333\u201343. https:\/\/doi.org\/10.1097\/00004347-199310000-00008.","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"8118_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/ncpendmet0887","volume":"4","author":"L Yassa","year":"2008","unstructured":"Yassa L, Sadow P, Marqusee E. Malignant struma ovarii. Nat Clin Pract Endocrinol Metab. 2008;4(8):469\u201372.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"8118_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13048-018-0383-2","volume":"11","author":"S Fujiwara","year":"2018","unstructured":"Fujiwara S, Tsuyoshi H, Nishimura T, Takahashi N, Yoshida Y. Precise preoperative diagnosis of struma ovarii with pseudo-Meigs\u2019 syndrome mimicking ovarian cancer with the combination of 131I scintigraphy and 18F\u2013FDG PET: case report and review of the literature. J Ovarian Res. 2018;11(1):11. https:\/\/doi.org\/10.1186\/s13048-018-0383-2.","journal-title":"J Ovarian Res"},{"issue":"4","key":"8118_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3109\/09513590.2014.995616","volume":"31","author":"B Gonzalez Aguilera","year":"2015","unstructured":"Gonzalez Aguilera B, Guerrero Vazquez R, Gros Herguido N, Sanchez Gallego F, Navarro GE. The lack of consensus in management of malignant struma ovarii. Gynecol Endocrinol. 2015;31(4):258\u20139. https:\/\/doi.org\/10.3109\/09513590.2014.995616.","journal-title":"Gynecol Endocrinol"},{"key":"8118_CR5","first-page":"133","volume-title":"Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series - volume IV","author":"A Hanby","year":"2004","unstructured":"Hanby A, Walker C. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series - volume IV. Lyon: IARC Press. Breast Cancer Res. 2004; 6(3): 133."},{"issue":"9","key":"8118_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1089\/105072501316973163","volume":"11","author":"A Checrallah","year":"2001","unstructured":"Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: an unusual presentation. Thyroid. 2001;11(9):889\u201392. https:\/\/doi.org\/10.1089\/105072501316973163.","journal-title":"Thyroid."},{"issue":"6","key":"8118_CR7","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00404-019-05329-z","volume":"300","author":"MR Siegel","year":"2019","unstructured":"Siegel MR, Wolsky RJ, Alvarez EA, Mengesha BM. Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature. Arch Gynecol Obstet. 2019;300(6):1693\u2013707. https:\/\/doi.org\/10.1007\/s00404-019-05329-z.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"8118_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/thy.2014.0328","volume":"25","author":"P Goffredo","year":"2015","unstructured":"Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA. Malignant struma ovarii: a population-level analysis of a large series of 68 patients. Thyroid. 2015;25(2):211\u20135. https:\/\/doi.org\/10.1089\/thy.2014.0328.","journal-title":"Thyroid."},{"issue":"3","key":"8118_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0090-8258(03)00141-0","volume":"89","author":"CP DeSimone","year":"2003","unstructured":"DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol. 2003;89(3):543\u20138. https:\/\/doi.org\/10.1016\/S0090-8258(03)00141-0.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"8118_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1754-9485.2012.02394.x","volume":"56","author":"RK Shrimali","year":"2012","unstructured":"Shrimali RK, Shaikh G, Reed NS. Malignant struma ovarii: the west of Scotland experience and review of literature with focus on postoperative management. J Med Imag Radiat Oncol. 2012;56(4):478\u201382. https:\/\/doi.org\/10.1111\/j.1754-9485.2012.02394.x.","journal-title":"J Med Imag Radiat Oncol"},{"issue":"2","key":"8118_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4158\/EP.15.2.167","volume":"15","author":"JF McGill","year":"2009","unstructured":"McGill JF, Sturgeon C, Angelos P. Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation. Endocr Pract. 2009;15(2):167\u201373. https:\/\/doi.org\/10.4158\/EP.15.2.167.","journal-title":"Endocr Pract"},{"issue":"4","key":"8118_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1089\/thy.2011.0162","volume":"22","author":"JL Marti","year":"2012","unstructured":"Marti JL, Clark VE, Harper H, Chhieng DC, Sosa JA, Roman SA. Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: a series of 4 patients and a review of 53 reported cases. Thyroid. 2012;22(4):400\u20136. https:\/\/doi.org\/10.1089\/thy.2011.0162.","journal-title":"Thyroid."},{"issue":"3","key":"8118_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/01443615.2011.645921","volume":"32","author":"S Jean","year":"2012","unstructured":"Jean S, Tanyi JL, Montone K, McGrath C, Lage-Alvarez MM, Chu CS. Papillary thyroid cancer arising in struma ovarii. J Obstet Gynaecol. 2012;32(3):222\u20136. https:\/\/doi.org\/10.3109\/01443615.2011.645921.","journal-title":"J Obstet Gynaecol"},{"key":"8118_CR14","doi-asserted-by":"publisher","unstructured":"Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol. 2009;28(5):405\u201322. https:\/\/doi.org\/10.1097\/PGP.0b013e3181a27777.","DOI":"10.1097\/PGP.0b013e3181a27777"},{"key":"8118_CR15","doi-asserted-by":"publisher","unstructured":"Li S, Yang T, Li X, Zhang L, Shi H, Cheng N, et al. FIGO stage IV and age over 55 years as prognostic predicators in patients with metastatic malignant Struma Ovarii. Front Oncol. 2020;10:584917. https:\/\/doi.org\/10.3389\/fonc.2020.584917.","DOI":"10.3389\/fonc.2020.584917"},{"key":"8118_CR16","doi-asserted-by":"publisher","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","DOI":"10.3322\/caac.21388"},{"issue":"3","key":"8118_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/PGP.0b013e3181bfb133","volume":"29","author":"R Shaco-Levy","year":"2010","unstructured":"Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ. Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol. 2010;29(3):212\u201327. https:\/\/doi.org\/10.1097\/PGP.0b013e3181bfb133.","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"8118_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1017\/S0022215112000904","volume":"126","author":"S Gunasekaran","year":"2012","unstructured":"Gunasekaran S, Kopecka E, Maung KH, England RJ. Struma ovarii and the thyroid surgeon. J Laryngol Otol. 2012;126(8):858\u201360. https:\/\/doi.org\/10.1017\/S0022215112000904.","journal-title":"J Laryngol Otol"},{"issue":"1","key":"8118_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11845-010-0467-5","volume":"181","author":"JP O'Neill","year":"2012","unstructured":"O'Neill JP, Burns P, Kinsella J. Papillary type thyroid carcinoma in an ovarian struma. Ir J Med Sci. 2012;181(1):115\u20137. https:\/\/doi.org\/10.1007\/s11845-010-0467-5.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"8118_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/01443610310001627209","volume":"24","author":"AN Griffiths","year":"2004","unstructured":"Griffiths AN, Jain B, Vine SJ. Papillary thyroid carcinoma of struma ovarii. J Obstet Gynaecol. 2004;24(1):92\u20133. https:\/\/doi.org\/10.1080\/01443610310001627209.","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"8118_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000063215","volume":"58","author":"I Kostoglou-Athanassiou","year":"2002","unstructured":"Kostoglou-Athanassiou I, Lekka-Katsouli I, Gogou L, Papagrigoriou L, Chatonides I, Kaldrymides P. Malignant struma ovarii: report of a case and review of the literature. Horm Res. 2002;58(1):34\u20138. https:\/\/doi.org\/10.1159\/000063215.","journal-title":"Horm Res"},{"issue":"6","key":"8118_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les etudes des cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149.","journal-title":"Cancer."},{"issue":"4","key":"8118_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin"},{"key":"8118_CR24","doi-asserted-by":"publisher","unstructured":"Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association stratification system. Thyroid. 2020;30(5):713\u20139. https:\/\/doi.org\/10.1089\/thy.2019.0688.","DOI":"10.1089\/thy.2019.0688"},{"issue":"2","key":"8118_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1210\/jc.2017-02255","volume":"103","author":"S Shah","year":"2018","unstructured":"Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid Cancer at high risk of recurrence. J Clin Endocrinol Metab. 2018;103(2):689\u201397. https:\/\/doi.org\/10.1210\/jc.2017-02255.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"8118_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1089\/thy.2006.16.1019","volume":"16","author":"K Kulkarni","year":"2006","unstructured":"Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16(10):1019\u201323. https:\/\/doi.org\/10.1089\/thy.2006.16.1019.","journal-title":"Thyroid."},{"key":"8118_CR27","doi-asserted-by":"publisher","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612\u20138. https:\/\/doi.org\/10.1097\/AOG.0b013e318264f794.","DOI":"10.1097\/AOG.0b013e318264f794"},{"issue":"7","key":"8118_CR28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1089\/thy.2016.0650","volume":"27","author":"Z Yang","year":"2017","unstructured":"Yang Z, Flores J, Katz S, Nathan CA, Mehta V. Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid. 2017;27(7):944\u201352. https:\/\/doi.org\/10.1089\/thy.2016.0650.","journal-title":"Thyroid."},{"key":"8118_CR29","doi-asserted-by":"publisher","unstructured":"Fujiwara S, Tsuyoshi H, Nishimura T, Takahashi N, Yoshida Y. Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of (131) I scintigraphy and (18) F-FDG PET: case report and review of the literature. J Ovarian Res. 2018;(1):11. https:\/\/doi.org\/10.1186\/s13048-018-0383-2.","DOI":"10.1186\/s13048-018-0383-2"},{"key":"8118_CR30","doi-asserted-by":"publisher","unstructured":"Shaco-Levy R, Peng RY, Snyder MJ, Osmond GW, Veras E, Bean SM, et al. Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior. Arch Pathol Lab Med. 2012;136(2):172\u20138. https:\/\/doi.org\/10.5858\/arpa.2011-0092-OA.","DOI":"10.5858\/arpa.2011-0092-OA"},{"key":"8118_CR31","doi-asserted-by":"publisher","unstructured":"van Velsen EFS, Visser WE, van den Berg SAA, Kam BLR, van Ginhoven TM, Massolt ET, et al. Longitudinal analysis of the effect of radioiodine therapy on ovarian Reserve in Females with differentiated thyroid Cancer. Thyroid. 2020;30(4):580\u20137. https:\/\/doi.org\/10.1089\/thy.2019.0504.","DOI":"10.1089\/thy.2019.0504"},{"key":"8118_CR32","doi-asserted-by":"publisher","unstructured":"Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid Cancer: a meta-analysis. Thyroid. 2017;27(5):651\u201360. https:\/\/doi.org\/10.1089\/thy.2016.0350.","DOI":"10.1089\/thy.2016.0350"},{"issue":"2","key":"8118_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12022-009-9097-8","volume":"21","author":"C Coyne","year":"2010","unstructured":"Coyne C, Nikiforov YE. RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol. 2010;21(2):144\u20137. https:\/\/doi.org\/10.1007\/s12022-009-9097-8.","journal-title":"Endocr Pathol"},{"issue":"3","key":"8118_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12022-007-0022-8","volume":"18","author":"O Boutross-Tadross","year":"2007","unstructured":"Boutross-Tadross O, Saleh R, Asa SL. Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol. 2007;18(3):182\u20136. https:\/\/doi.org\/10.1007\/s12022-007-0022-8.","journal-title":"Endocr Pathol"},{"key":"8118_CR35","doi-asserted-by":"publisher","unstructured":"Poli R, Scatolini M, Grosso E, Maletta F, Gallo M, Liscia D, et al. Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. Endocrine. 2020;70(3):661. https:\/\/doi.org\/10.1007\/s12020-020-02514-y.","DOI":"10.1007\/s12020-020-02514-y"},{"issue":"4","key":"8118_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12022-015-9394-3","volume":"26","author":"A Tan","year":"2015","unstructured":"Tan A, Stewart CJ, Garrett KL, Rye M, Cohen PA. Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in Struma Ovarii. Endocr Pathol. 2015;26(4):296\u2013301. https:\/\/doi.org\/10.1007\/s12022-015-9394-3.","journal-title":"Endocr Pathol"},{"key":"8118_CR37","doi-asserted-by":"publisher","unstructured":"Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, et al. Genomic alterations in fatal forms of non-anaplastic thyroid Cancer: identification of MED12 and RBM10 as novel thyroid Cancer genes associated with tumor virulence. Clin Cancer Res. 2017;23(19):5970\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1183.","DOI":"10.1158\/1078-0432.CCR-17-1183"},{"key":"8118_CR38","doi-asserted-by":"publisher","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdz400.","DOI":"10.1093\/annonc\/mdz400"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08118-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T10:12:15Z","timestamp":1617963135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08118-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8118"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08118-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"23 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Peking Union Medical College Hospital (reference number: S-K1198). The written informed consent was obtained from all the participants in our hospital in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patients. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}